Results 171 to 180 of about 13,094 (219)

The incidence of anti-HMGCR immune-mediated necrotizing myopathy: an Australian and UK retrospective multi-site cohort study. [PDF]

Rheumatology (Oxford)
Khoo T, Tan E, Limaye V, Gunawardena H, Sadler R, Lamb JA, Lyu X, Brusch A, Needham M, Austin K, Bahadori A, Buch MH, Tomaszewski M, Lilleker JB, Chinoy H.   +14 more
europepmc   +1 more source

Lipid liquid-crystalline nanoparticles as a suitable platform for accommodating sensitive membrane proteins: monitoring the activity of HMG-CoA reductase. [PDF]

J Nanobiotechnology
Zaborowska-Mazurkiewicz M, Nazaruk E, Bilewicz R.   +2 more
europepmc   +1 more source

Intrinsic Factors Influencing Simvastatin and Simvastatin Acid Pharmacokinetics: Age-Related Studies in Thai Adults and Cross-Population Comparisons. [PDF]

Clin Transl Sci
Srimatimanon T, Udomnilobol U, Chariyavilaskul P, Siwamogsatham S, Praditpornsilpa K, Vorasettakarnkij Y, Petchlorlian A, Vanwong N, Piriyapongsa J, Tipsombatboon P, Yodsurang V, Prueksaritanont T.   +11 more
europepmc   +1 more source

Simvastatin-loaded liposomal nanoparticles as treatment for adenomyosis in a patient-derived xenograft mouse model: a pilot study. [PDF]

J Obstet Gynaecol
Michel R, Vincent KL, Kirschen GW, Motamedi M, Saada J, Yang J, Ozpolat B, Kilic GS, Borahay MA.   +8 more
europepmc   +1 more source

Clinical repercussions of statin use during pregnancy: a review of the literature. [PDF]

Rev Bras Ginecol Obstet
Lins Serafim J, Lucas Santos de Menezes Teles P, Souza Lima AK, Dos Santos Coelho J, Luna Maranhão Conrado P, Luna VLM, Galvão PVM, Conrado GAM.   +7 more
europepmc   +1 more source

HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia. [PDF]

Cochrane Database Syst Rev
Saishoji Y, Kim S, Banno M, Kohmura K, Kataoka Y, Tsujimoto Y.   +5 more
europepmc   +1 more source

Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets.

Health Technol Assess
Mihaylova B, Wu R, Zhou J, Williams C, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Parnell R, Armitage J, Gray A, Simes J, Baigent C.   +13 more
europepmc   +1 more source

Reduction of Brain β-Amyloid（Aβ) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments （APP-CTFs) and Aβ Clearance

Reduction of Brain β-Amyloid（Aβ) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments （APP-CTFs) and Aβ Clearance
openaire  

Hydroxymethylglutaryl–CoA reductase inhibitor inhibits induction of nitric oxide synthase in 3T3–L1 preadipocytes

Life Sciences, 2007
Preadipocytes are considered to play a role in adipose tissue inflammation in obesity. The purpose of this study was to determine whether hydroxymethylglutaryl-CoA reductase inhibitor (statin) modulates the nitric oxide (NO) production via inducible NO synthase (iNOS) in preadipocytes.
Kazushige Dobashi, Shunsuke Araki, Kazuyasu Kubo, Rinko Kawagoe, Y. Yamamoto, Akira Shirahata   +5 more
openalex   +3 more sources

The Natural Products as Hydroxymethylglutaryl-Coa Reductase Inhibitors

Letters in Drug Design & Discovery, 2018
High cholesterol and triglyceride levels are mainly related to further generation of lifethreating metabolism disorders including cardiovascular system diseases. Therefore, hypercholesterolemia (i.e., also referred to as hyperlipoproteinemia) is a serious disease state, which must be controlled.
Hayrettin Ozan Gülcan, Serkan Yiğitkan, İlkay Erdoğan Orhan   +2 more
openalex   +3 more sources